An FDA 483 observation is a formal notice issued by an FDA investigator when they identify conditions that may violate regulations during a pharmaceutical facility inspection. Left unaddressed, 483 observations can escalate to Warning Letters, consent decrees, or facility shutdowns. AES specializes in rapid 483 remediation — eliminating root causes before they become enforcement actions.

Most AES engagements run 3 to 6 months depending on the severity of operational or quality failures. Our fastest documented result was zero FDA 483 observations at a re-inspection in month four of engagement.

Lean Six Sigma is a data-driven methodology that eliminates waste and reduces process variation in manufacturing operations. In pharma, it reduces deviation rates, cuts OPEX, and improves compliance — simultaneously. AES is Lean Six Sigma certified and implements it directly on the manufacturing floor.

A fractional COO provides senior operational leadership on a part-time or project basis — without the cost of a full-time executive hire. AES deploys fractional COO services for PE-backed pharma facilities that need immediate operational leadership during turnarounds, acquisitions, or compliance crises.

Yes. AES partners with PE sponsors to assess, stabilize, and optimize pharma manufacturing assets within hold periods. We provide EBITDA recovery, FDA risk neutralization, and clean quality systems that support exit valuations.